Drug Profile


Alternative Names: Citrate/taurolidine/heparin; CRMD 003; CRMD 004; Heparin/citrate/taurolidine; Heparin/taurolidine/citrate; Neutrolin; Taurolidine/citrate/heparin; Taurolidine/heparin/citrate

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ND Partners
  • Developer CorMedix
  • Class Alkanesulfonic-acids; Antibacterials; Anticoagulants; Citrates; Heparins; Small molecules; Thiadiazines
  • Mechanism of Action Cell adhesion molecule inhibitors; Deoxyribonuclease 1 stimulants; Factor Xa inhibitors; Heparanase inhibitors; Lipopolysaccharide inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Catheter infections

Highest Development Phases

  • Marketed Catheter infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Catheter-infections(Prevention) in European Union (Gel)
  • 02 Aug 2017 CorMedix receives favourable correspondence from the US FDA for the ongoing phase III LOCK-IT-100 trial in Catheter infections (Prevention)
  • 12 Apr 2017 Cormedix and Hemotech enter into commercial collaboration for citrate/heparin/taurolidine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top